Innovative new system for AMD Treatment based on monochromatic Low Light Therapy.
Low-level monochromatic light induces a restorative effect on the disease-affected tissue;
AMD SpecraLight Therapy controls the disease and prevents it from spreading further;
AMD SpectraLight uses trans-pupilary macula irradiation with a calculated sub-threshold dose of monochromatic light;
AMD SpectraLight has been used successfully with hundreds of patients and it is a safe therapy for AMD;
Wavelength, energy, exposure and mode of irradiation, all constitute critical parameters of the clinical treatment protocol.
AMD Markets
Over 14 million people in the EU27 states are projected to have AMD. Up to 1 million new cases every year.
For more information or to license this innovation:
- Log In
to view the innovation's details
- Sign Up
with discount code "ECOS"
